Product Information
INSULIN GLARGINE-YFGN U100 PEN is a generic product labeled by Biocon Biologics Inc., priced at $5.9249 per ML under NDC 83257001532. Its NADAC has been published 138 times since Feb 14, 2024.
Strength
100 [iU]/mL
Manufacturer
Biocon Biologics Inc.NDC
83257001532
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
INSULIN GLARGINEApproval Type
Biologic (BLA)
FDA Application
BLA761201On Market Since
7/28/2023
Pharmacological Classes
Price Statistics
The NADAC for INSULIN GLARGINE-YFGN U100 PEN has been published 138 times since Feb 14, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.9249 per ML |
|---|---|
| All-time high | $5.9645 (Aug 14, 2024) |
| All-time low | $5.8943 (Feb 14, 2024) |
| 52-week high | $5.9377 |
| 52-week low | $5.9163 |
| Median price | $5.9270 |
| Average price | $5.9282 |
| Largest weekly change | +0.9% (Apr 17, 2024) |
| Weeks tracked | 138 |
| Tracking since | Feb 14, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Biocon Biologics Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
insulin Glargine-yfgn market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Insulin Analog class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of INSULIN GLARGINE-YFGN U100 PEN?
The current National Average Drug Acquisition Cost (NADAC) for INSULIN GLARGINE-YFGN U100 PEN, manufactured by Biocon Biologics Inc., is $5.9249 per ML (NDC 83257001532), effective Sep 30, 2026.
How has the price of INSULIN GLARGINE-YFGN U100 PEN changed over time?
Over the history we have for it, the NADAC for INSULIN GLARGINE-YFGN U100 PEN has held within roughly two percent of its current level. It has been tracked across 138 weekly CMS publications since Feb 14, 2024.
What are the highest and lowest recorded NADAC prices for INSULIN GLARGINE-YFGN U100 PEN?
Since Feb 14, 2024, the NADAC for INSULIN GLARGINE-YFGN U100 PEN has ranged from a low of $5.8943 (Feb 14, 2024) to a high of $5.9645 (Aug 14, 2024), with a median of $5.9270 per ML.
Are there cheaper alternatives to INSULIN GLARGINE-YFGN U100 PEN?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as INSULIN GLARGINE-YFGN U100 PEN in a comparable dosage form, but none are currently priced below it.
Who manufactures INSULIN GLARGINE-YFGN U100 PEN?
INSULIN GLARGINE-YFGN U100 PEN (NDC 83257001532) is labeled by Biocon Biologics Inc., and CMS classifies it as a generic product.